Wave Life Sciences Ltd. (WVE)
NASDAQ: WVE · Real-Time Price · USD
8.17
-0.46 (-5.28%)
Mar 31, 2025, 10:45 AM EDT - Market open

Company Description

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform.

The company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.

It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD).

The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD.

Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

Wave Life Sciences Ltd.
Wave Life Sciences logo
Country Singapore
Founded 2012
IPO Date Nov 11, 2015
Industry Biotechnology
Sector Healthcare
Employees 288
CEO Paul B. Bolno

Contact Details

Address:
Marina One East Tower, 7 Straits View No.12-00
Singapore, 018936
Singapore
Phone 65 6236 3388
Website wavelifesciences.com

Stock Details

Ticker Symbol WVE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001631574
CUSIP Number Y95308105
ISIN Number SG9999014716
SIC Code 2834

Key Executives

Name Position
Dr. Paul B. Bolno M.B.A., M.D. President, Chief Executive Officer and Director
Dr. Gregory L. Verdine Ph.D. Founder and Director
Kyle B. Moran CFA Chief Financial Officer and Principal Accounting Officer
Dr. Chandra Vargeese Ph.D. Chief Technology Officer
Dr. Erik Ingelsson M.D., Ph.D. Chief Scientific Officer
Kate Rausch Head of Investor Relations
Linda Rockett J.D. Senior Vice President and General Counsel
Dr. Christopher Francis Ph.D. Senior Vice President of Corporate Development and Head of Emerging Areas
Daryn Lewis Senior Vice President and Head of Human Resources
Dr. Sridhar Vaddeboina Ph.D. Senior Vice President of Chemistry, Manufacturing and Controls

Latest SEC Filings

Date Type Title
Mar 26, 2025 8-K Current Report
Mar 20, 2025 144 Filing
Mar 7, 2025 144 Filing
Mar 4, 2025 10-K Annual Report
Mar 4, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 5, 2025 SCHEDULE 13G/A Filing
Jan 13, 2025 8-K Current Report
Nov 25, 2024 144 Filing
Nov 20, 2024 8-K Current Report